OBJECTIVE: To evaluate the predictive value of seven biomarkers, which individually have been shown to be independent predictors, for use in a combined multimarker model for long-term cardiovascular outcome after non-ST-segment elevation acute coronary syndrome (NSTEACS). DESIGN AND SETTING: Levels of high-sensitivity C-reactive protein (hsCRP), myeloperoxidase, pregnancy-associated plasma protein A, placental growth factor (PlGF), soluble CD40 ligand (sCD40L), interleukin 10 (IL-10) and troponin-T (TnT) were determined in patients enrolled in the CAPTURE trial. Cox proportional hazard regression analyses were applied to evaluate the relation between biomarkers and the occurrence of all-cause mortality or non-fatal myocardial infarction (MI). PATIENTS: 1090 patients with NSTEACS. MAIN OUTCOME MEASURE: All-cause mortality and non-fatal MI during a median follow-up of 4 years. RESULTS: The composite endpoint was reached by 15.3% of patients. Admission levels of TnT >0.01 μg/l (adjusted HR 1.8), IL-10 <3.5 ng/l (1.7), myeloperoxidase >350 μg/l (1.5) and PlGF >27 ng/l (1.9) remained significant predictors for the incidence of all-cause mortality or non-fatal MI after multivariable adjustment for other biomarkers and clinical characteristics, whereas hsCRP, pregnancy-associated plasma protein A and sCD40L were only associated with the endpoint in univariate analysis. A multimarker model consisting of TnT, IL-10, myeloperoxidase and PlGF predicted 4-year event rates that varied between 6.0% (all markers normal) and 35.8% (three or more biomarkers abnormal). CONCLUSION: In patients with NSTEACS, biomarkers characterising distinct aspects of the underlying atherosclerotic process and myocardial damage of the initial cardiac event can assist in predicting long-term adverse cardiac outcomes. The use of combinations of selected biomarkers adds incremental predictive value to further risk stratification in an otherwise seemingly homogeneous NSTEACS population.
OBJECTIVE: To evaluate the predictive value of seven biomarkers, which individually have been shown to be independent predictors, for use in a combined multimarker model for long-term cardiovascular outcome after non-ST-segment elevation acute coronary syndrome (NSTEACS). DESIGN AND SETTING: Levels of high-sensitivity C-reactive protein (hsCRP), myeloperoxidase, pregnancy-associated plasma protein A, placental growth factor (PlGF), soluble CD40 ligand (sCD40L), interleukin 10 (IL-10) and troponin-T (TnT) were determined in patients enrolled in the CAPTURE trial. Cox proportional hazard regression analyses were applied to evaluate the relation between biomarkers and the occurrence of all-cause mortality or non-fatal myocardial infarction (MI). PATIENTS: 1090 patients with NSTEACS. MAIN OUTCOME MEASURE: All-cause mortality and non-fatal MI during a median follow-up of 4 years. RESULTS: The composite endpoint was reached by 15.3% of patients. Admission levels of TnT >0.01 μg/l (adjusted HR 1.8), IL-10 <3.5 ng/l (1.7), myeloperoxidase >350 μg/l (1.5) and PlGF >27 ng/l (1.9) remained significant predictors for the incidence of all-cause mortality or non-fatal MI after multivariable adjustment for other biomarkers and clinical characteristics, whereas hsCRP, pregnancy-associated plasma protein A and sCD40L were only associated with the endpoint in univariate analysis. A multimarker model consisting of TnT, IL-10, myeloperoxidase and PlGF predicted 4-year event rates that varied between 6.0% (all markers normal) and 35.8% (three or more biomarkers abnormal). CONCLUSION: In patients with NSTEACS, biomarkers characterising distinct aspects of the underlying atherosclerotic process and myocardial damage of the initial cardiac event can assist in predicting long-term adverse cardiac outcomes. The use of combinations of selected biomarkers adds incremental predictive value to further risk stratification in an otherwise seemingly homogeneous NSTEACS population.
Authors: Yvan Devaux; Melanie Bousquenaud; Sophie Rodius; Pierre-Yves Marie; Fatiha Maskali; Lu Zhang; Francisco Azuaje; Daniel R Wagner Journal: BMC Med Genomics Date: 2011-12-05 Impact factor: 3.063
Authors: Rohit M Oemrawsingh; K Martijn Akkerhuis; Victor A Umans; Bas Kietselaer; Carl Schotborgh; Eelko Ronner; Timo Lenderink; Anho Liem; David Haitsma; Pim van der Harst; Folkert W Asselbergs; Arthur Maas; Anton J Oude Ophuis; Ben Ilmer; Rene Dijkgraaf; Robbert-Jan de Winter; S Hong Kie The; Alexander J Wardeh; Walter Hermans; Etienne Cramer; Ron H van Schaik; Imo E Hoefer; Pieter A Doevendans; Maarten L Simoons; Eric Boersma Journal: BMJ Open Date: 2016-12-23 Impact factor: 2.692
Authors: Andrew R Kolodziej; Mohamed Abo-Aly; Eman Elsawalhy; Charles Campbell; Khaled M Ziada; Ahmed Abdel-Latif Journal: Mediators Inflamm Date: 2019-06-25 Impact factor: 4.711
Authors: Barbara Elisabeth Stähli; Keiko Yonekawa; Lukas Andreas Altwegg; Christophe Wyss; Danielle Hof; Philipp Fischbacher; Andreas Brauchlin; Georg Schulthess; Pierre-Alexandre Krayenbühl; Arnold von Eckardstein; Martin Hersberger; Michel Neidhart; Steffen Gay; Igor Novopashenny; Regine Wolters; Michelle Frank; Manfred Bernd Wischnewsky; Thomas Felix Lüscher; Willibald Maier Journal: PLoS One Date: 2014-06-03 Impact factor: 3.240
Authors: Michelle L O'Donoghue; David A Morrow; Christopher P Cannon; Petr Jarolim; Nihar R Desai; Matthew W Sherwood; Sabina A Murphy; Robert E Gerszten; Marc S Sabatine Journal: J Am Heart Assoc Date: 2016-05-20 Impact factor: 5.501